Lifecore Biomedical Inc. (LFCR) is a leading, high-quality developer and manufacturer of premium injectable hyaluronic acid (HA). Since its inception, the company has been committed to enhancing and improving the quality of life for individuals worldwide. Lifecore manufactures sterile injectable products, primarily for ophthalmic applications, and offers separate chemical and microbial testing services for its pharmaceutical and biotechnology clients.
Lifecore's commitment to maintaining a high-quality development and production process is amplified by its state-of-the-art facilities, including its FDA-registered, ISO 13485:2016 certified manufacturing facility located in Chaska, Minnesota. Although it operates on a global level, the company maintains a strong presence in the United States. Its diverse clientele ranges from small domestic start-ups to large multinational medical device companies.
The company's history dates back to 1981. Lifecore started as a supplier of biomaterials for surgical products but soon shifted its focus to HA production, as it recognized the high demand for high-quality, durable and natural products in the heathcare industry. Its innovative product offering caters specifically to three rapidly growing segments of the healthcare industry: ophthalmic, orthopedic, and veterinary.
In addition to its core business of developing and manufacturing HA products, Lifecore provides a wide array of services for the pharmaceutical and medical device industries. These include fill-finish services, fermentation of recombinant proteins, and aseptic filling in syringes and vials. The company also provides contract manufacturing services, and has been recognized for its dedication to quality, innovation, and customer focus.
Lifecore’s dedication to ensuring patient safety is evident in its engagement in clinical trials and studies. The company remains committed to being at the forefront of technological and scientific advancement in the biotechnology industry. Innovation is a cornerstone of Lifecore's philosophy, as they strive not only to meet the needs of their clients, but to anticipate and respond to changing conditions and demands within the dynamic medical industry.
In addition to focusing on the quality of its products and services, Lifecore also places great emphasis on its corporate social responsibility. The company actively engages in a variety of sustainability initiatives and is dedicated to stewardship of the environment.
In summary, Lifecore Biomedical is a company with a strong presence in the biotechnology field and a commitment to excellence and innovation. Its high-quality HA products, customer-centered approach, and sustainable practices have made it a leading player in the industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Lifecore Biomedical, Inc. (LFCR) reported a significant loss of $40.1 million, or $1.08 per share, in its third quarter. The agricultural and food packaging products company also posted revenues of $25.3 million for the same period. This financial data was generated using information from Zacks Investment Research.
Lifecore Biomedical reported a decrease in Q2 2026 revenues to $34.2 million, down 6.2% from the prior year, and a net loss of $6.2 million. Despite this, the company reaffirmed its 2026 guidance, expecting revenue between $120 to $125 million and adjusted EBITDA of $20.5 to $25 million, driven by strategic growth, advancing its development pipeline, and adding new programs. Operational highlights include successful audits, expected doubled fill-finish demand from 2027, and significant cost reduction efforts, with SG&A and R&D expenses cut by $16.2 million since 2024.
William Blair analyst Jared Haase downgraded Lifecore Biomedical (LFCR) to a Hold rating on October 3. Despite this, the company reported increased quarterly revenue of $34.17 million, up from $31.11 million the previous year, and a reduced GAAP net loss of $6.16 million compared to $9.99 million in the prior year. The consensus among analysts for Lifecore Biomedical remains a Hold with an average price target of $6.28.
Lifecore Biomedical (Nasdaq: LFCR) saw its stock close up significantly following the announcement of its acquisition by Webster Equity Partners. The deal is valued at up to $663.7 million, including contingent value rights, offering common stockholders $6.28 per share in cash plus CVRs. This transaction represents a substantial premium to Lifecore's recent closing price and is expected to support the company's future growth objectives.